Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.160
-0.030 (-1.37%)
May 14, 2025, 10:24 AM - Market open
Company Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology.
Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4.
The company was founded in 2018 and is headquartered in New York, New York.
Nuvation Bio Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 220 |
| CEO | David Hung |
Contact Details
Address: 1500 Broadway, Suite 1401 New York, New York 10036 United States | |
| Phone | 332 208 6102 |
| Website | nuvationbio.com |
Stock Details
| Ticker Symbol | NUVB |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001811063 |
| CUSIP Number | 67080N101 |
| ISIN Number | US67080N1019 |
| Employer ID | 85-0862255 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David T. Hung M.D. | Founder, President, Chief Executive Officer and Chairman |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer |
| Colleen Sjogren | Chief Commercial Officer |
| Philippe Sauvage | Chief Financial Officer and Principal Financial Officer |
| Moses Makunje CPA | Vice President of Finance and Principal Accounting and Financial Officer |
| Dr. Stephen Dang Ph.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Stacy Markel | Chief People Officer |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer |
| Kerry A. Wentworth | Chief Regulatory Officer |
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| May 2, 2025 | 144 | Filing |
| Apr 28, 2025 | SCHEDULE 13G/A | Filing |
| Apr 8, 2025 | ARS | Filing |
| Apr 8, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 6, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 6, 2025 | 10-K | Annual Report |